1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Carbonic Anhydrase

Carbonic Anhydrase

Carbonate dehydratase

Carbonic anhydrase (CA) is a zinc-containing enzyme that catalyzes the reversible hydration of carbon dioxide: CO2 + H2O ⇋ HCO3- + H+. Eight genetically distinct carbonic anhydrase enzyme families (α-, β-, γ- δ-, ζ-, η-, θ- and ι- CAs) were described to date. Carbonic anhydrases are involved in numerous physiological and pathological processes. Many of them are important therapeutic targets with the potential to be inhibited to treat a range of disorders including oedema, glaucoma, obesity, cancer, epilepsy, and osteoporosis.

The carbonic anhydrase reaction is involved in many physiological and pathological processes, including respiration and transport of CO2 and bicarbonate between metabolizing tissues and lungs; pH and CO2 homeostasis; electrolyte secretion in various tissues and organs; biosynthetic reactions (such as gluconeogenesis, lipogenesis, and ureagenesis); bone resorption; calcification; and tumorigenicity. α-CAs are Zn2+ metalloproteins expressed in animals, vertebrates, prokaryotes, fungi, algae, protozoa, and plants. Sixteen mammalian α-CA isoforms are known to be involved in many diseases such as glaucoma, edema, epilepsy, obesity, hypoxic tumors, neuropathic pain, arthritis, neurodegeneration, etc.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-181350
    CAIX/XII/NAMPT-IN-1
    Inhibitor
    CAIX/XII/NAMPT-IN-1 is a triple inhibitor of carbonic anhydrase IX/XII and nicotinamide phosphoribosyltransferase (NAMPT) with a hCA IX Ki of 78.1 nM, hCA XII Ki of 64.4 nM, and hNAMPT IC50 of 168 nM. CAIX/XII/NAMPT-IN-1 induces apoptosis, ROS accumulation, suppresses ERK/AKT signaling, inhibits DNA synthesis, and causes mitochondrial dysfunction. CAIX/XII/NAMPT-IN-1 exerts antiproliferative effects against multiple cancer cells under normoxic and hypoxic conditions. CAIX/XII/NAMPT-IN-1 can be used for the research of cancer, such as renal carcinoma, glioblastoma and colorectal cancer.
    CAIX/XII/NAMPT-IN-1
  • HY-146819
    CAIX/CAXII-IN-1
    Compound 9 is the most effective against tumor specific Ca ix/ca XII (ki=29.1 and 8.8 nm), so it is possible to evaluate its cytotoxicity and selectivity to HepG-2, HCT-116 and MCF-7 cancer cell lines in vitro, and its IC50 values to tumor cells are 1.78, 1.94 and 3.07, respectively μ M. It showed that it had obvious cytotoxicity.
    CAIX/CAXII-IN-1
  • HY-N1393S1
    2-Methoxybenzoic acid-d3
    2-Methoxybenzoic acid (NSC 3778; O-Methylsalicylic acid; Salicylic acid methyl ether)-d3 is deuterium-labeled 2-Methoxybenzoic acid (HY-N1393). 2-Methoxybenzoic acid is a natural compound with potential salicylate-like effect. 2-Methoxybenzoic acid inhibits carbonic anhydrase activity, elevates intraplatelet cyclic guanosine monophosphate level, and suppresses cytosolic phospholipase A2 phosphorylation. 2-Methoxybenzoic acid suppresses platelet reactivity, including decreased spreading, retraction, and aggregation in platelets. 2-Methoxybenzoic acid ameliorates arterial thrombosis in a dose-dependent manner without affecting normal hemostasis in mice. 2-Methoxybenzoic acid can be used for the research of arterial thrombosis.
    2-Methoxybenzoic acid-d<sub>3</sub>
  • HY-B0588R
    Brinzolamide (Standard)
    Inhibitor
    Brinzolamide (Standard) is the analytical standard of Brinzolamide. This product is intended for research and analytical applications. Brinzolamide (AL-4862) is a selective carbonic anhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research.
    Brinzolamide (Standard)
  • HY-B0588A
    Brinzolamide hydrochloride
    Inhibitor
    Brinzolamide (AL-4862) hydrochloride is a selective carbonic anhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research.
    Brinzolamide hydrochloride
  • HY-W013316R
    Lasamide (Standard)
    Inhibitor
    Lasamide (Standard) is the analytical standard of Lasamide. This product is intended for research and analytical applications. Lasamide is a potent human Carbonic Anhydrase inhibitor with Ki values of 7.54 and 2.76 nM for hCAXII and hCAIX, respectively.
    Lasamide (Standard)
  • HY-B0397A
    Dichlorphenamide disodium
    Inhibitor
    Dichlorphenamide (Diclofenamide) disodium is an orally active, specific, carbonic anhydrase inhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research.
    Dichlorphenamide disodium
  • HY-159982
    SH7s
    Inhibitor
    SH7s is a potent carbonic anhydrases inhibitor, with Kis of 15.9 and 55.2 nM for hCA IX and hCA XII, respectively. SH7s is also a hypoxia-mediated chemo-sensitizing agent in colorectal cancer cells.
    SH7s
  • HY-182070
    Carbonic anhydrase-IN-38
    Inhibitor
    Carbonic anhydrase-IN-38 (compound 5c) is a carbonic anhydrase inhibitor with antiproliferative activity, with Ki values of 576.2 nM, 41.3 nM and 86.9 nM against hCA VII, hCA IX and hCA XII, respectively. Carbonic anhydrase-IN-38 can be used in research related to triple-negative breast cancer and glioblastoma.
    Carbonic anhydrase-IN-38
  • HY-152001
    hCAIX-IN-24
    Inhibitor
    hCAIX-IN-24 is a potent and selectively hCA IX inhibitor with an KI value of 32.1 nM. hCAIX-IN-24 shows anti-proliferative activity.
    hCAIX-IN-24
  • HY-129781
    L-650719
    Inhibitor
    L-650719 is a topical carbonic anhydrase inhibitor (CAI) with a Ki of 10 nM for CA II. L-650719 has shown good intraocular pressure-lowering effects in a rabbit model. L-650719 may be used in glaucoma research.
    L-650719
  • HY-163268
    Carbonic anhydrase inhibitor 18
    Inhibitor
    Carbonic anhydrase inhibitor 18 (Compound 9) is a human carbonic anhydrase (hCA) isoform inhibitor, with Kis of 604.8, 333.6, 1.9 and 6.7 nM for hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonic anhydrase inhibitor 18 can be used for the research of cancer.
    Carbonic anhydrase inhibitor 18
  • HY-181510
    CAII-IN-14
    Inhibitor
    CAII-IN-14 (Compound 3o) is a human carbonic anhydrase II (hCA II) inhibitor with a Ki value of 1.65 nM. CAII-IN-14 also inhibits hCA I(Ki = 6.15 nM) and hCA IX(Ki = 5.43 nM). CAII-IN-14 exhibits predicted drug-like properties.
    CAII-IN-14
  • HY-115998
    Carbonic anhydrase inhibitor 11
    Inhibitor
    Carbonic anhydrase inhibitor 11 (compound VI) is a potent, selective carbonic anhydrase inhibitor. Carbonic anhydrase inhibitor 11 shows Ki values of 40, 39, 200 and 900 nM against CA II, IX, and XII, respectively.
    Carbonic anhydrase inhibitor 11
  • HY-149011
    CA IX-IN-1
    Inhibitor
    CA IX-IN-1 (compound 12g) is an effective and selective inhibitor of hCA IX with IC50 value of 7 nM. CA IX-IN-1 exhibits antitumor activity.
    CA IX-IN-1
  • HY-157135
    hCAIX-IN-19
    hCAIX-IN-19 is a sulfonamides inhibitor against hCA IX with an inhibition constant (KI ) of 6.2 nM and show good selectivity over hCA I (hCA I/ hCA IX = 117).
    hCAIX-IN-19
  • HY-125575
    FC11409B
    Inhibitor
    FC11409B is an ureido-sulfamate carbonic anhydrase IX (CAIX) inhibitor. FC11409B inhibits proliferation and migration of breast cancer cell lines in both hypoxic (0.5% O2) and normoxic conditions (21% O2). FC11409B also inhibits 3D spheroid of breast cancer subtypes invasion. FC11409B is promising for research of breast and ovarian cancers.
    FC11409B
  • HY-170560
    AChE/hCA I-IN-1
    Inhibitor
    AChE/hCA I-IN-1 (Compound L3) is the inhibitor for acetylcholinesterase (AChE) and carbonic anhydrase (CA), that inhibits AChE, hCA I and hCA II with IC50 of 302, 265 and 283 nM, respectively.
    AChE/hCA I-IN-1
  • HY-147922
    hCAI/II-IN-2
    Inhibitor
    hCAI/II-IN-2 (compound 2b) is a potent dual hCA I/II inhibitor with Ki values of 40.97, 15.15 and 61.88 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-2 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity.
    hCAI/II-IN-2
  • HY-149012
    AChE/hCA I/II-IN-1
    Inhibitor
    AChE/hCA I/II-IN-1 (Compound 6) is a potent inhibitor of AChE/Hca with IC50 values of 22.21, 60.79 and 66.64 nM for AChE, Hca Ⅰ and Hca Ⅱ. AChE/hCA I/II-IN-1 can be used for the rsearch for glaucoma, Alzheimer's disease, diabetes.
    AChE/hCA I/II-IN-1
Cat. No. Product Name / Synonyms Species Source

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.